0 CHECKOUT

Premature Labor (Tocolysis) - Pipeline Review, H1 2015

  • ID: 3112103
  • January 2015
  • 46 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Actavis plc
  • GlaxoSmithKline plc
  • ObsEva SA
  • MORE

Premature Labor (Tocolysis) - Pipeline Review, H1 2015

Summary

This, ‘Premature Labor (Tocolysis) - Pipeline Review, H1 2015’, provides an overview of the Premature Labor (Tocolysis)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Premature Labor (Tocolysis), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Premature Labor (Tocolysis) and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Actavis plc
  • GlaxoSmithKline plc
  • ObsEva SA
  • MORE

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Premature Labor (Tocolysis) Overview
Therapeutics Development
Pipeline Products for Premature Labor (Tocolysis) - Overview
Pipeline Products for Premature Labor (Tocolysis) - Comparative Analysis
Premature Labor (Tocolysis) - Therapeutics under Development by Companies
Premature Labor (Tocolysis) - Therapeutics under Investigation by Universities/Institutes
Premature Labor (Tocolysis) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Premature Labor (Tocolysis) - Products under Development by Companies
Premature Labor (Tocolysis) - Products under Investigation by Universities/Institutes
Premature Labor (Tocolysis) - Companies Involved in Therapeutics Development
Actavis plc
GlaxoSmithKline plc
Kissei Pharmaceutical Co., Ltd.
ObsEva SA
Premature Labor (Tocolysis) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AT-814 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
bedoradrine sulfate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug for Postpartum Depression and Premature Labor - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OBE-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OBE-002 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Progesterone Second Generation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
retosiban - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Agonize Progesterone Receptor for Preterm Birth - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Premature Labor (Tocolysis) - Recent Pipeline Updates
Premature Labor (Tocolysis) - Dormant Projects
Premature Labor (Tocolysis) - Discontinued Products
Premature Labor (Tocolysis) - Product Development Milestones
Featured News & Press Releases
Aug 17, 2007: MediciNova Reports Phase Ib Clinical Study Results For MN-221 A Novel Treatment For Preterm Labor
Mar 14, 2005: MediciNova Initiates A Phase I Clinical Trial With MN-221
Mar 24, 2004: MediciNova Acquires Phase II Premature Labor Compound
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Premature Labor (Tocolysis), H1 2015
Number of Products under Development for Premature Labor (Tocolysis) - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Comparative Analysis by Unknown Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Investigation by Universities/Institutes, H1 2015
Premature Labor (Tocolysis) - Pipeline by Actavis plc, H1 2015
Premature Labor (Tocolysis) - Pipeline by GlaxoSmithKline plc, H1 2015
Premature Labor (Tocolysis) - Pipeline by Kissei Pharmaceutical Co., Ltd., H1 2015
Premature Labor (Tocolysis) - Pipeline by ObsEva SA, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Premature Labor (Tocolysis) Therapeutics - Recent Pipeline Updates, H1 2015
Premature Labor (Tocolysis) - Dormant Projects, H1 2015
Premature Labor (Tocolysis) - Discontinued Products, H1 2015

List of Figures
Number of Products under Development for Premature Labor (Tocolysis), H1 2015
Number of Products under Development for Premature Labor (Tocolysis) - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Note: Product cover images may vary from those shown
3 of 4

Actavis plc
GlaxoSmithKline plc
Kissei Pharmaceutical Co., Ltd.
ObsEva SA

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PURCHASING OPTIONS

HAVE A QUESTION?

EMAIL US VIEW FAQs

RELATED PRODUCTS from Db

Our Clients

  • Actavis
  • Smith & Nephew PLC.
  • Bayer AG
  • Hologic Inc.
  • Abbott Laboratories Ltd.
  • Polpharma SA